Home Alzheimer’s Disease Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma

Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma

Savolitinib showed encouraging efficacy data and an improved safety profile compared to the standard of care sunitinib (Sutent) in patients with MET-driven papillary renal cell carcinoma (RCC), according to study results presented at the 2020 ASCO Virtual Scientific Program.

The highly selective MET-tyrosine kinase inhibitor also yielded fewer grade 3 or 4 adverse events (AEs) while requiring fewer dose modifications than sunitinib, which performed more poorly than the external retrospective data anticipated.

“Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile versus sunitinib,” said lead study author Toni K Choueiri, MD, director, Lank Center for Genitourinary Oncology and the Kidney Cancer Center, Dana-Farber Cancer Institute, in his presentation of the data.

Median progression-free survival (PFS)…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments